Safety and Efficacy of Sunitinib in Patients from Italy with Metastatic Renal Cell Carcinoma: Final Results from an Expanded-Access Trial

Cora N. Sternberg,Fabio Calabrò,Sergio Bracarda,Giacomo Cartenì,Giovanni Lo Re,Enzo Maria Ruggeri,Umberto Basso,Giampietro Gasparini,L. Ciuffreda,Vittorio Ferrari,A. Bonetti,Elena Fea,Donatello Gasparro,Davide Tassinari,Roberto Labianca,Cristina Masini,Kolette Fly,Ke Zhang,Subramanian Hariharan,Barbara Capaccetti,Camillo Porta

Safety and Efficacy of Sunitinib in Patients from Italy with Metastatic Renal Cell Carcinoma: Final Results from an Expanded-Access Trial

2015

Objectives: Patients with metastatic renal cell carcinoma (mRCC) received sunitinib in a global expanded-access program (EAP). Here, we report the efficacy and sa

Keywords:

Pathology
Medicine
Sunitinib malate
Renal cell carcinoma
Expanded access trial
Oncology
Sunitinib
Internal medicine
in patient
receptor tyrosine kinase inhibitor

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations